The clinical landscape of 2026 is witnessing a resurgence of oncolytic virus research, as scientists successfully engineer viral strains that selectively replicate within malignant cells while leaving healthy ones intact. This biological strategy, supported by recent updates to the Global Bio-Safety Framework, is providing a new lifeline for patients with refractory glioblastoma and pancreatic...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)